SCHEMBL16624267

SCHEMBL16624267

COCc1nc(O)c(C(=O)OC)cc1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
KMT2A Q03164 4/20 0.46
MEN1 O00255 1/20 0.46
RXFP1 Q9HBX9 2/20 0.45
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA7 P43166 3/20 0.42
CA9 Q16790 3/20 0.42
CA14 Q9ULX7 3/20 0.42
PDK2 Q15119 1/20 0.42
PDK4 Q16654 1/20 0.42
POLB P06746 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 3/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16616461 0.85 NPC1 (0.47) NPC1RAB9AKMT2ARXFP1CA12
SCHEMBL16624282 0.82 KDM4E (0.52) NPC1RAB9AKMT2AMEN1RXFP1
SCHEMBL16616378 0.82 HSP90AA1 (0.41) NPC1RAB9AKMT2ARXFP1CA12
SCHEMBL16624279 0.82 NPC1 (0.47) NPC1RAB9AKMT2AMEN1RXFP1
SCHEMBL16616416 0.75 GAA (0.51) NPC1RAB9AKMT2ACA12CA1
SCHEMBL8751819 0.75 CA12 (0.43) NPC1RAB9ACA12CA1CA2
SCHEMBL28826850 0.73 NPC1 (0.45) NPC1RAB9AKMT2AMEN1RXFP1
SCHEMBL16624313 0.73 CNR1 (0.53) NPC1RAB9AKMT2AMEN1RXFP1
SCHEMBL127097 0.73 NPC1 (0.46) NPC1RAB9AKMT2AMEN1RXFP1
SCHEMBL6840685 0.73 HCAR2 (0.44) NPC1RAB9AKMT2AMEN1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751878-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-9751878-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-20160237087-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-18 US disclosed
US-20160237087-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-18 US disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099777-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 NPC1 2111/4885RAB9A 3341/4885KMT2A 3500/4885
US-20160237087-A1 HETEROCYCLIC COMPOUNDS SSTR5, SSTR4, SSTR2 NPC1 2202/4885RAB9A 3387/4885KMT2A 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.